Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
€8.30

€8.30

18.940%
1.322
18.940%
€27.98
 
22.08.24 / Frankfurt WKN: A2QJRU / Symbol: EYPT / Name: EyePoint Pharma / Stock / Biotechnology & Medical Research / Small Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.

EyePoint Pharmaceuticals Inc. Stock

A very strong showing by EyePoint Pharmaceuticals Inc. today, with an increase of €1.32 (18.940%) compared to yesterday's price.
We see a rather positive sentiment for EyePoint Pharmaceuticals Inc. with 20 Buy predictions and 1 Sell predictions.
Based on the current price of 8.3 € the target price of 27 € shows a potential of 225.22% for EyePoint Pharmaceuticals Inc. which would more than double the current price.
Criterium "Worthwhile Investment for the next years" is seen as the biggest plus for EyePoint Pharmaceuticals Inc. stock. Negative votes have not been in the majority for any criteria for this stock

Pros and Cons of EyePoint Pharmaceuticals Inc. in the next few years

Pros
?
C******** o* t** e**********
?
W********* I********* f** t** n*** y****
?
B****
Cons
?
G***** c******* t* c**********
?
S********** s********
?
M***** P*******
Tell us your opinion to access the 'Wisdom of the Crowds'

Performance of EyePoint Pharmaceuticals Inc. vs. its peers

Security Change(%) 1w 1m 1y YTD 3y 5y
EyePoint Pharmaceuticals Inc. 18.940% 13.045% 1.990% -38.045% -60.840% -4.023% -37.906%
Evolus Inc 2.940% 16.667% 21.739% 64.706% 54.696% 51.351% -
Ardelyx Inc. 5.770% 6.941% 7.836% 67.751% -1.903% 364.754% 79.034%
Coherus Bioscien. 4.560% 8.696% -18.879% -71.053% -59.293% -90.553% -93.737%

sharewise BeanCounterBot

The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.
Last updated at 2023-10-31

Betrachtet man zunächst die allgemeinen Finanzen von EyePoint Pharma (EYPT), einem Unternehmen aus der Branche für Biotechnologie und medizinische Forschung, lassen sich einige Schlüsseltrends erkennen. Mit einer Marktkapitalisierung von 185 Millionen US-Dollar rangiert das Unternehmen im mittleren Segment des Markts. Dies deutet darauf hin, dass es trotz der Tatsache, dass es in einer Branche tätig ist, die bekanntermaßen hohe Entwicklungskosten hat, eine bemerkenswerte finanzielle Stabilität aufweist.

Der erste Eindruck, der sich aus diesen Zahlen ergibt, ist jedoch keineswegs überwältigend positiv. Einen erheblichen Einfluss darauf hat der deutlich negative Betriebsgewinn (EBITDA) von -84 Millionen US-Dollar sowie weitere wichtige Kennzahlen wie die Profitmarge und die operative Marge, die beide ebenfalls im negativen Bereich liegen.

Wie bei jeder Bewertung eines Unternehmens gilt es, die positiven Aspekte gegen die negativen abzuwägen. Bei EyePoint Pharma ist eines der hervorstechenden positiven Elemente der Buchwert von 1,67 USD. Dies kann ein Indikator dafür sein, dass das Unternehmen über bedeutende Vermögenswerte verfügt - ein potenzielles Sicherheitsnetz, falls es Schwierigkeiten begegnen sollte.

Comments

Prediction Buy
Perf. (%) 8.13%
Target price 26.500
Change
Ends at 13.08.25

EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) had its price target lowered by analysts at JPMorgan Chase & Co. from $32.00 to $29.00. They now have an "overweight" rating on the stock.
Ratings data for EYPT provided by MarketBeat
Show more

Prediction Buy
Perf. (%) -0.34%
Target price 26.149
Change
Ends at 28.06.25

EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $28.00 price target on the stock.
Ratings data for EYPT provided by MarketBeat
Show more

Prediction Buy
Perf. (%) 10.87%
Target price 27.981
Change
Ends at 27.06.25

EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $30.00 price target on the stock.
Ratings data for EYPT provided by MarketBeat
Show more